Laurus Labs has stepped up its Research and Development (R&D) initiatives with a pipeline of 60 products. Its sterile R&D labs, commissioned in 2022, are already working on several priority projects, which are either under review or under development, having a market size of over USD 40 billion.

Laurus has also invested in ImmnoACT, which set up an advanced GMP CAR-T cell therapy facility in Mumbai, and initiated a Phase-II for HCAR-19 in lymphoma and Leukemia, post positive Phase-I data results.

During FY23, Laurus filed its first New Drug Application (NDA) for novel HIV-pediatric product using oral dissolving film technology, and aspires to set an innovative pipeline in other therapeutic areas.

Further, the investment made towards expanding non-ARV formulation infrastructure with a total commissioned capacity of 10 billion units will be complemented by an improved demand visibility in ARV business, CMO portfolio, as also key product approvals across the US, Europe and Canada.

In its portfolio-led investment, the company has a product-specific approach based on complexity and economies of scale, and will prioritise disruptive technologies that blend scientific opportunity and value.

The Hyderabad-based company, clocked Rs 6,041 crore revenue in FY23 marking a 22 percent increase over the previous year,with a 3.5 percent spend on R&D in the last financial year (FY).